Free Trial
NASDAQ:MDWD

MediWound Q2 2025 Earnings Report

MediWound logo
$18.63 -0.15 (-0.80%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$18.61 -0.02 (-0.08%)
As of 08/8/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MediWound EPS Results

Actual EPS
N/A
Consensus EPS
-$0.55
Beat/Miss
N/A
One Year Ago EPS
N/A

MediWound Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.68 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

MediWound Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

MediWound Earnings Headlines

MediWound to Report Second Quarter 2025 Financial Results
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.
See More MediWound Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediWound? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediWound and other key companies, straight to your email.

About MediWound

MediWound (NASDAQ:MDWD), a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

View MediWound Profile

More Earnings Resources from MarketBeat